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Tuberculosis is a major global public health concern. In 2016, 
the World Health Organization (WHO) estimated that there 
were 10.4 million new tuberculosis patients worldwide and 1.8 
million tuberculosis-related deaths.1 Diabetes mellitus affects 
the host immune response to tuberculosis, and people with 
diabetes have a threefold increased risk of developing active 
tuberculosis.2 In 2015, the International Diabetes Federa-
tion estimated that there were 415 million adults living with 
diabetes mellitus worldwide, many undiagnosed, and mostly 
living in low- and middle-income countries where there is 
often a high burden of tuberculosis.1,3 Diabetes patients with 
concurrent tuberculosis also have poorer tuberculosis treat-
ment outcomes,4,5 so it is important to identify these patients 
promptly to optimize treatment.
Current WHO guidelines for diagnosing diabetes mel-
litus in healthy people at high risk of the disease are based 
on identifying diabetes symptoms (polyuria, polydipsia, 
unexplained weight loss), in combination with measurement 
of fasting plasma glucose, oral glucose tolerance or glycated 
haemoglobin (HbA1c). Repeated laboratory measurements 
are needed if the patient does not have symptoms.4,6 WHO 
recommends screening newly diagnosed tuberculosis patients 
for diabetes, but has not recommended any specific method.7 
The symptoms of active tuberculosis disease overlap with those 
of diabetes, and the inflammation associated with infectious 
disease can increase insulin resistance, which complicates the 
diagnosis of diabetes.8
Several risk scores have been developed to detect undi-
agnosed diabetes based on clinical data.9 However, the scores 
are strongly based on anthropometric markers (body mass 
index, waist–hip ratio) that are affected by the weight loss as-
sociated with tuberculosis disease. Previous studies screening 
tuberculosis patients for undiagnosed diabetes have mainly 
considered operational issues and feasibility.9–12 Few studies 
have compared the accuracy of more than one screening test, 
including simple and affordable tests such as risk scores and 
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Objective To evaluate the performance of diagnostic tools for diabetes mellitus, including laboratory methods and clinical risk scores, in 
newly-diagnosed pulmonary tuberculosis patients from four middle-income countries.
Methods In a multicentre, prospective study, we recruited 2185 patients with pulmonary tuberculosis from sites in Indonesia, Peru, Romania 
and South Africa from January 2014 to September 2016. Using laboratory-measured glycated haemoglobin (HbA1c) as the gold standard, 
we measured the diagnostic accuracy of random plasma glucose, point-of-care HbA1c, fasting blood glucose, urine dipstick, published 
and newly derived diabetes mellitus risk scores and anthropometric measurements. We also analysed combinations of tests, including a 
two-step test using point-of-care HbA1cwhen initial random plasma glucose was ≥ 6.1 mmol/L.
Findings The overall crude prevalence of diabetes mellitus among newly diagnosed tuberculosis patients was 283/2185 (13.0%; 95% 
confidence interval, CI: 11.6–14.4). The marker with the best diagnostic accuracy was point-of-care HbA1c (area under receiver operating 
characteristic curve: 0.81; 95% CI: 0.75–0.86). A risk score derived using age, point-of-care HbA1c and random plasma glucose had the best 
overall diagnostic accuracy (area under curve: 0.85; 95% CI: 0.81–0.90). There was substantial heterogeneity between sites for all markers, 
but the two-step combination test performed well in Indonesia and Peru.
Conclusion Random plasma glucose followed by point-of-care HbA1c testing can accurately diagnose diabetes in tuberculosis patients, 
particularly those with substantial hyperglycaemia, while reducing the need for more expensive point-of-care HbA1c testing. Risk scores 
with or without biochemical data may be useful but require validation.
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some point-of-care tests. Furthermore, 
studies have not estimated the accuracy 
of two-step screening processes or risk 
scores for diabetes diagnosis derived 
specifically in tuberculosis patients. 
We therefore aimed to evaluate the 
performance of diagnostic tools for 
diabetes mellitus, including standard 
glucose testing, two-step screening and 
clinical risk scores, in newly-diagnosed 




The Concurrent Tuberculosis and 
Diabetes Mellitus (TANDEM) study 
aimed to improve the screening and 
management of combined tuberculosis 
and diabetes mellitus.13 This multicen-
tre, prospective study has field sites in 
Indonesia, Peru, Romania and South 
Africa. These are countries with diverse 
health-care systems and population de-
mographics, but a relatively high burden 
of tuberculosis and an increasing preva-
lence of diabetes.1,3 Further information 
on the study design and methods are 
available from a data repository.14
Study procedures
At each site we recruited patients with 
newly diagnosed pulmonary tuberculo-
sis based on symptoms, chest X-rays and 
sputum culture examination. Consecu-
tive pulmonary tuberculosis patients 
presenting for treatment at study sites af-
ter January 2014 were recruited up until 
September 2016. We excluded patients 
from the diagnostic accuracy analysis 
if they were known to have diabetes 
(i.e. self-reporting a previous diagnosis 
of diabetes mellitus from a health-care 
practitioner or on antidiabetic medica-
tion). We used laboratory measurement 
of HbA1c as the gold standard for the 
diagnosis of diabetes, with a diagnostic 
cut-off point ≥ 6.5%.4 To account for 
potential transient hyperglycaemia, 
we made secondary analyses, defining 
diabetes by repeated raised HbA1c at 
the end of tuberculosis treatment with 
a higher cut-off at baseline (≥ 7.0%)8 or 
by fasting plasma glucose.
We screened for diabetes at the 
time of recruitment, and patients with 
initial raised HbA1c were offered a 
confirmatory test. We aimed to repeat 
the HbA1c test for all patients at the 
end of tuberculosis treatment, which 
was 6 months after recruitment. Other 
data collected include demographic 
data, height, weight, family history 
of diabetes, self-reported gestational 
diabetes or delivery of a large baby 
(> 4 kg weight), anthropometric mea-
surements (waist circumference and 
weight-to-hip ratio), levels of physical 
activity and consumption of fruits and 
vegetables. We recorded point-of-care 
diabetes markers (HbA1c), random 
plasma glucose and fasting plasma 
glucose for those with an initial ran-
dom plasma glucose ≥ 6.1 mmol/L and 
urinary dipstick for glucose. Point-of-
care HbA1c measurements were made 
using the HemoCue® HbA1c 501 test 
(HemoCue AB, Ängelholm, Sweden). 
In Romania, HemoCue® was not avail-
able, so we used QuoTest® (EKF Diag-
nostics, Cardiff, United Kingdom of 
Great Britain and Northern Ireland). 
In addition, we sent blood samples 
for HbA1c testing in an accredited 
laboratory with certification from the 
National Institutes of Diabetes and 
Digestive and Kidney Diseases.15 We 
calculated three previously published 
diabetes risk scores for each patient: 
the Finnish diabetes risk score,16 the 
Indian risk score17 and the Oman dia-
betes risk scores.18 We selected these 
scores based on a recent review9 due 
to their higher sensitivity in detecting 
diabetes, repeatability in validation 
studies, demographic diversity and 
complementary variables.
We also evaluated a two-step com-
bination test, which was a random 
plasma glucose test, followed by a 
point-of-care HbA1c test in certain 
circumstances. If the random plasma 
glucose test result was < 6.1 mmol/L 
the individual was determined not to 
have diabetes, and no further testing 
was performed. For random plasma 
glucose ≥ 11.1 mmol/L, the individual 
was determined to have diabetes and 
no further testing was performed. For 
random plasma glucose between these 
values a point-of-care HbA1c test would 
be performed. This combination was 
chosen since the initial test is cheap and 
widely available, and low levels are more 
likely to rule out diabetes. The second 
test is more expensive, but used only 
on those with random plasma glucose 
≥ 6.1 mmol/L. Neither test requires the 
patient to fast, so both can be performed 
in one clinic visit.
Statistical methods
In cross-sectional analysis, we compared 
the diagnostic accuracy of random 
plasma glucose, fasting plasma glucose, 
point-of-care HbA1c, urine dipstick and 
the three published diabetes risk scores 
and the two-step combination test. We 
calculated sensitivity, specificity and the 
area under the receiver operating char-
acteristic (ROC) curve. We defined cut-
offs for each diagnostic measure using 
established values from the published 
literature,6,9,19,20 and two data-driven 
values, one chosen to provide the maxi-
mum combination of sensitivity and 
specificity, the other a sensitivity of at 
least 80%. Sample size calculations were 
carried out for a pre-specified sensitivity 
and precision.14
We developed new risk scores using 
logistic regression models and backward 
variable selection. These scores aimed 
to assess the diagnostic accuracy of 
combining random plasma glucose and 
point-of-care HbA1c with anthropo-
metric and risk factor measurements. 
The variables included were derived 
from previously published risk scores,9 
including age, family history of diabetes, 
physical activity (active for more than 
30 minutes per day), daily consump-
tion of fruits and vegetables, taking 
antihypertensive medications, waist cir-
cumference, weight-to-hip ratio, body 
mass index, random plasma glucose 
and point-of-care HbA1c. To maximize 
diagnostic accuracy we also used first- 
and second-order fractional polynomial 
methods for the continuous predictors 
random plasma glucose, point-of-care 
HbA1c, age and body mass index.14 In a 
separate model for women, we included 
history of gestational diabetes and deliv-
ery of a large baby. The full TANDEM 
score included all variables retained 
in the backward selection model, with 
P < 0.1 required to remain in the model. 
The restricted TANDEM score followed 
the same method, but omitted point-of-
care HbA1c as a covariate due to the cost 
implications.
We summarized the areas under 
the ROC curve and sensitivity and 
specificity estimates over the whole 
study population. Due to considerable 
diagnostic heterogeneity, we stratified 
estimates by country. We also assessed 
diagnostic accuracy in the sensitivity 
analyses when defining diabetes using 
fasting plasma glucose (≥ 7 mmol/L), 
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where fasting plasma glucose was avail-
able. Statistical analyses were performed 
using SAS, version 9.4 (SAS Institute, 
Cary, United States of America).
Results
Baseline characteristics
A total of 2185 patients with newly-
diagnosed pulmonary tuberculosis were 
enrolled: 748 in Indonesia, 600 in Peru, 
506 in Romania and 331 in South Af-
rica. Tuberculosis was bacteriologically 
confirmed in 1867 (85.4%) patients, with 
the rest being diagnosed clinically. A 
quarter of patients (538; 24.7%) reported 
a previous diagnosis of tuberculosis, 
363 (64.0%) of whom had completed 
treatment. At screening, 2032 patients 
(93.2%) had cough, 1690 (77.8%) had 
weight loss and 1466 (67.7%) reported 
night sweats. Among patients agreeing 
to testing, co-infection with human im-
munodeficiency virus was found in one 
patient (0.2%) in Romania, 26 (3.5%) 
in Indonesia, 23 (3.8%) in Peru and 31 
(9.4%) in South Africa.
For the diagnostic accuracy analysis 
we excluded 183 patients with self-
reported diabetes before recruitment 
and also 63 with no measurement of 
laboratory HbA1c. Baseline charac-
teristics and diabetes diagnostic test 
data are summarized in Table 1 for 
the 1939 newly-diagnosed pulmonary 
tuberculosis patients with no previous 
diabetes diagnosis: 649 in Indonesia, 
562 in Peru, 469 in Romania and 259 in 
South Africa. In total, 100 patients were 
newly diagnosed with diabetes, a crude 
prevalence of 5.2% (95% CI: 4.2–6.2), 
ranging from 3.0% (95% CI: 1.8–4.8; 
17 patients) in Peru to 6.9% (95% CI: 
4.2–10.8; 18 patients) in South Africa. 
The overall crude prevalence of diabetes 
mellitus (both new and previously diag-
nosed) was 13.0% (95% CI: 11.6–14.4; 
283 patients).
Diabetes risk scores
Logistic regression parameter estimates 
and diabetes risk scores are shown in 
Table 2. In univariate analysis, age, fam-
ily history of diabetes, physical activity, 
taking antihypertensive medications, 
waist circumference, body mass index 
category, random plasma glucose and 
point-of-care HbA1c were all associated 
with incident diabetes (P < 0.1). Data on 
the relationships of age, random plasma 
glucose and point-of-care HbA1c with 
the probability of diabetes are available 
from the repository.14
In the full multivariate stepwise 
regression model the fractional poly-
nomial form of age, random plasma 
glucose2 and log(point-of-care HbA1c) 
were selected as independent predictors 
of diabetes. In the restricted model, 
the fractional polynomial form of age, 
physical activity, body mass index 
category and random plasma glucose2 
were selected as predictors. In a separate 
model for women, history of gestational 
diabetes and delivery of a big baby were 
assessed, although neither approached 
statistical significance (P > 0.2). The 
parameter estimates from these models 
were used to construct two new risk 
score equations (Box 1). 
Diagnostic accuracy of markers
There was considerable heterogeneity 
in the degree of laboratory-measured 
HbA1c associated with diabetes between 
countries (Fig. 1). In Indonesia and 
Peru, the median HbA1c level for new 
diabetes cases was 10.8% (interquartile 
range, IQR: 8.0–12.9) and 7.9% (IQR: 
6.8–10.6), respectively, far above the 
recognized 6.5% diagnostic cut-off for 
diabetes. In Romania and South Africa 
the levels were 6.7% (IQR: 6.6–6.9) and 
6.8% (IQR: 6.6–7.0), respectively.
Fig. 2 summarizes the accuracy of 
key diagnostic tests (details for each 
country are available from the reposi-
tory14). All diabetes markers were more 
accurate in Indonesia and Peru, where 
patients newly diagnosed with diabetes 
had higher levels of HbA1c (Fig. 1). 
Sensitivity and specificity were lower 
in Romania and South Africa, where 
newly diagnosed patients had mod-
est elevations of HbA1c. The two-step 
combination of achieved some of the 
highest combinations of sensitivity and 
specificity overall compared with other 
tests. For example, in Indonesia, the 
two-step combination had a sensitiv-
ity of 88.2% (95% CI: 72.5–96.7) and 
specificity of 96.0% (95% CI: 94.2–97.4). 
The sensitivity was higher (94.1%; 95% 
CI: 80.3–99.3) with a different lower 
point-of-care HbA1c cut-off (6.0%), 
without a substantial cost to specificity 
(91.1%; 95% CI: 88.5–93.2). In Roma-
nia, however, the respective sensitiv-
ity was much lower at 37.5% (95% CI: 
18.8–59.4) and specificity was 87.8% 
(95% CI: 84.1–90.9), even using a point-
of-care HbA1c cut-off of 6.0%. The full 
TANDEM score performed better in 
South Africa (0.74: 95% CI: 0.61‒0.87), 
relative to point-of-care HbA1c and 
the two-step combination. However, 
this option would be more expensive, 
requiring both random plasma glu-
cose and point-of-care HbA1c tests as 
well as other risk markers. Sensitivity 
could possibly be further increased in 
Romania and South Africa with lower 
thresholds for each test, but the lower 
specificity would result in more expen-
sive confirmatory tests.
Table 3 shows the combined diag-
nostic accuracy of individual diabetes 
markers, risk scores and published 
diabetes risk scores. The full TAN-
DEM score achieved the highest area 
under the ROC curve overall (0.85; 
95% CI: 0.81–0.90), followed by the 
restricted TANDEM score (0.84; 95% 
CI: 0.79–0.88), and a single point-of-
care HbA1c measure (0.81; 95% CI: 
0.75–0.86). The single random plasma 
glucose measure was also useful (0.77; 
95% CI: 0.70–0.83). The three previously 
published diabetes risk scores had simi-
lar diagnostic accuracy as determined by 
the area under the ROC curve (0.70 to 
0.72; 95% CI: 0.64–0.77). However, age 
alone was a stronger predictor of undi-
agnosed diabetes than these risks scores 
(0.75; 95% CI: 0.70–0.80). Weight-to-hip 
ratio and body mass index had poor 
diagnostic accuracy.
The optimal diagnostic cut-offs for 
the full and restricted TANDEM scores 
were ≥ 12.4 and ≥ 3.5, respectively. The 
optimal diagnostic cut-off for a single 
point-of-care HbA1c measurement 
was ≥ 6.0%, which achieved higher 
sensitivity (75.8% versus 59.3%), but 
lower specificity (70.4% versus 88.7%) 
than the standard ≥ 6.5% cut-off. For 
random plasma glucose, the standard 
cut-off of ≥ 11.1 mmol/L achieved 
very high specificity (99.3%), but low 
sensitivity (36.1%). The optimal cut-off 
of ≥ 6.9 mmol/L had higher sensitivity 
(62.9%), but lower specificity (83.3%). 
The standard ≥ 7.0 mmol/L cut-off 
for fasting plasma glucose achieved 
high specificity (98.4%), but low sen-
sitivity (35.6%), while the optimal 
cut-off for fasting plasma glucose was 
≥ 5.2 mmol/L.
The two-step combination of ran-
dom plasma glucose and point-of-care 
HbA1c (≥ 6.0%) achieved sensitivity of 
63.4% and specificity of 89.3%, com-
parable accuracy to a single point-of-
care HbA1c test ≥ 6.5%. The modest 
sensitivity was the result of combining 
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four populations with heterogeneous 
distributions of HbA1c among those 
with newly diagnosed diabetes (Fig. 1).
All screening tests performed sub-
stantially better when diabetes status 
was classified at the end of tuberculosis 
treatment at 6 months (repeated HbA1c 
≥ 6.5%). For example, using the two-step 
combination of random plasma glu-
cose (≥ 6.1 mmol/L) and point-of-care 
HbA1c (≥ 6.5%), sensitivity increased 
to over 90% and specificity to 100% 
(available from the repository14). Simi-
larly, with a conservative gold standard 
definition of diabetes (HbA1c ≥ 7.0%), 
the overall diagnostic accuracy of all 
diabetes markers increased considerably 
(Fig. 2; Table 3).
When diabetes was defined by 
fasting plasma glucose ≥ 7.0 mmol/L, 
diagnostic accuracy of all markers 
was lower than with HbA1c. However, 
the strongest diagnostic metrics were 
similar (data are available from the 
repository14).
Discussion
Early diagnosis of diabetes mellitus 
in patients presenting with tubercu-
losis may lead to improved treatment 
outcomes and reduced mortality. Our 
study compared many potential dia-
betes screening procedures in patients 
diagnosed with tuberculosis, including 
point-of-care tests, and new and existing 
risk scores, in varied settings and patient 
ethnicities.
We found a significant prevalence 
of previously undiagnosed diabetes in 
newly diagnosed tuberculosis patients. 
While the screening tests were only 
performed in tuberculosis patients 
with no previous diabetes diagnosis, 
nearly twice as many patients with both 
tuberculosis and diabetes were identi-
fied simply by asking about previous 
diagnosis and medication. Over the 
four sites combined, derived risk scores, 
point-of-care HbA1c alone and a two-
step combination of random plasma 
glucose and point-of-care HbA1c were 
the best-performing methods for diabe-
tes screening. The two-step combination 
is appealing as point-of-care HbA1c 
testing is only required for those with 
random plasma glucose ≥ 6.1 mmol/L. 
In this study population, the combined 
test reduced the need for point-of-care 
HbA1c testing by 70%, potentially sav-
ing costs (Laurence Y, London School 
of Hygiene & Tropical Medicine, un-
Table 2. Univariate and multivariate logistic regression models; development of risk 
scores in the Concurrent Tuberculosis and Diabetes Mellitus study, 2014–2016




β OR (95% CI) β P β P
Age, per year 0.05 1.06 
(1.04–1.07)





       β1 0.010 NA
d 0.0073 0.0039 0.0077 0.0012
       β2 −0.0022 NA
d −0.0016 0.0060 −0.0017 0.0021

















0.45 1.6 (0.6–4.0) NA NA NA NA
Waist 
circumference: 
male > 94 cm; 
female > 80 cm
1.01 2.7 (1.7–4.5) NA NA NA NA
Waist-to-hip 
ratio: male 
> 0.90; female 
> 0.80
0.24 1.3 (0.9–1.9) NA NA NA NA
Body mass 
indexe 
       ≤ 25 kg/m2 Ref. Ref. NA NA NA NA
       < 30 kg/m2 0.86 2.4 (1.3–4.3) NA NA 0.36 0.36









0.030 NAd 0.019 < 0.0001 0.025 < 0.0001
Point-of-care 
HbA1c, per %
0.85 2.4 (2.0–2.7) NA NA NA NA
Log (point-of-
care HbA1c): β1
6.87 NAd 5.04 < 0.0001 NA NA
CI: confidence interval; HbA1c: glycated haemoglobin; NA: not applicable; OR: odds ratio; Ref. reference 
category; TANDEM: Concurrent Tuberculosis and Diabetes Mellitus study.
a  TANDEM scores were derived from multivariate backward selection logistic regression including all 
covariates significant in univariate models (P < 0.15) as candidate variables. The values for the full score 
ranged from 8.7–33.5 (median 11.3) and the restricted score 1.1–26.1 (median 2.9).
b  Restricted risk scores omitted point-of-care HbA1c from the covariates. 
c  Second order fractional polynomial was calculated as: β1 Age2 + β2 Age2 log(Age). 
d  Odds ratios were omitted for fractional polynomial parameters; the continuous probability plots are 
available from authors’ data repository.14 
e  Global body mass index P-values: univariate 0.0002; restricted TANDEM score 0.087.
Note: New diabetes mellitus cases were defined using a single HbA1c measurement (≥ 6.5%).
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published data, 2018).21 Further, the two 
steps can be completed in one clinic visit 
without prior fasting by patients, allow-
ing rapid diagnosis. Fasting tests can be 
difficult to obtain in tuberculosis clinics. 
In this study the fasting plasma glucose 
was missing for approximately 45% of 
the patients for whom it was indicated 
(those with an initial random plasma 
glucose ≥ 6.1 mmol/L). In contrast, we 
were able to obtain an HbA1c measure-
ment from about 95% of patients. In our 
study, health-care workers were also 
sometimes reluctant to ask patients to 
return in a state of fasting, as they felt 
that antituberculosis medication should 
ideally be taken with food to reduce 
nausea (and increase patient adherence). 
There was thus a strong preference 
among staff and patients for a screening 
strategy that could be completed rapidly, 
in a single visit, without prior fasting.
The three published scores per-
formed poorly at detecting diabetes 
among tuberculosis patients. All three 
scores were derived in the general 
population and rely heavily on body 
mass index and waist circumference,16–18 
which are often affected in tuberculosis 
patients. Median body mass index of 
the participants was below 19 kg/m2 in 
Indonesia and South Africa in this study, 
which may have contributed to the poor 
accuracy of the scores.
The risk scores we derived dem-
onstrated strong diagnostic accuracy 
but they require validation in other 
populations. The restricted TANDEM 
score included body mass index with 
parameters calibrated to tuberculosis 
patients with lower body mass. Accuracy 
of the restricted TANDEM score was 
only slightly lower, and it may be useful 
in settings where point-of-care HbA1c 
testing is not possible.
There was considerable heterogene-
ity between study settings in the distri-
bution of HbA1c in patients with un-
diagnosed diabetes. This heterogeneity 
affected the diagnostic accuracy for most 
screening tests and may reflect differ-
ences in disease prevalence or health-
system issues (such as quality of diabetes 
services, health insurance coverage and 
access to tuberculosis services).22 Conse-
quently, regional circumstances need to 
be taken into account when developing 
best local practice.
Due to pragmatic difficulties dur-
ing the intensive phase of tuberculosis 
care, diabetes was defined consistently 
on a single HbA1c measurement in 
Box 1. Two new risk scores for diabetes mellitus
Full TANDEM score = 0.0073(Age)2−0.0016(Age)2log(Age)+0.019(RPG)2+5.04log (point-of-care 
HbA1c)
Restricted TANDEM score = 0.0077(Age)2−0.0017(Age)2log(Age)+0.025(RPG)2+0.36(if 25 ≤ BMI 
≤ 30)+1.34(if BMI > 30)+0.64(if < 30 minutes physical activity/day)
BMI: body mass index; HbA1c: glycated haemoglobin; RPG: random plasma glucose; TANDEM: 
Concurrent Tuberculosis and Diabetes Mellitus study.
Fig. 1. Distribution of laboratory-measured glycated haemoglobin in patients with 
newly diagnosed tuberculosis recruited to the Concurrent Tuberculosis and 
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2.5 6.5 10.5 14.5 18.5
2.5 6.5 10.5 14.5 18.5
2.5 6.5 10.5 14.5 18.5
No diabetes mellitus (615 patients)
Diabetes mellitus (34 patients)
No diabetes mellitus (545 patients)
Diabetes mellitus (17 patients)
No diabetes mellitus (438 patients)
Diabetes mellitus (31 patients)
No diabetes mellitus (241 patients)





Laboratory-measured glycated haemoglobin (%)
Note: New diabetes mellitus was defined by laboratory-measured glycated haemoglobin ≥ 6.5%.
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this study, though individuals with a 
repeated HbA1c measure below 6.5% 
were not included in the case definition. 
We also performed secondary analyses 
using a conservative gold-standard 
diabetes definition and based on dia-
betes status at the end of tuberculosis 
treatment (6 months after baseline). 
In both these analyses, the diagnostic 
accuracy of all diabetes markers was 
markedly improved, and the two-step 
combination of random plasma glucose 
and point-of-care HbA1c achieved both 
sensitivity and specificity > 90%.
In practice, the type of screening 
tests used are often dictated by local 
circumstances, such as the opportu-
nity for patient follow-up, feasibility 
of fasting and costs associated with the 
tests.11 A cross-sectional study in India 
compared the diagnostic performance 
of HbA1c and fasting plasma glucose to 
oral glucose tolerance as the gold stan-
dard.12 The authors reported that HbA1c 
performed better than fasting plasma 
glucose among tuberculosis patients.12 
This contrasts with the general popu-
lation, in whom HbA1c tests may be 
less sensitive.23 WHO approved HbA1c 
testing for diagnosis of diabetes in 
2011.10 However, few studies have used 
the method in tuberculosis patients,24,25 
despite its practical benefits in requiring 
only a single non-fasting measurement 
and having less day-to-day and intra-day 
variation than blood glucose.11 Concerns 
have been raised about the accuracy of 
HbA1c testing in patients with anaemia. 
In particular, iron-deficiency anaemia 
may overestimate HbA1c,26 especially 
among people with normal or mod-
erately raised HbA1c (< 6.5%),27 while 
haemolytic anaemia can underestimate 
HbA1c.26 In our study there was no 
difference in mean HbA1c between 
moderate, mild and non-anaemic tuber-
culosis patients,14 a finding supported 
by another cohort study from India.28 
HbA1c appeared to be somewhat lower 
in those with severe anaemia, but with 
only 26 such individuals in our cohort, 
we lacked the statistical power to explore 
this further. A cautious approach to 
interpreting HbA1c in the presence of 
severe anaemia may be warranted.
In summary the two-step combina-
tion of random plasma glucose followed 
by point-of-care HbA1c testing if the 
random plasma glucose was above a 
set threshold appeared feasible and 
performed consistently well across sites. 
The combination performed especially 
well when based on diabetes confirmed 
at 6 months or using a conservative 
definition of diabetes. Most tests did not 
perform well in sites where many pa-
tients had borderline values of HbA1c, 
suggesting that mild elevations of any 
diabetes marker should be treated with 
caution at the beginning of tuberculosis 
treatment. Marginal hyperglycaemia 
may not be treated initially due to the 
potential for drug interactions, adverse 
events and possible impact on adherence 
to tuberculosis drugs.22 Such borderline 
diabetes patients should be offered re-
peat testing at the end of tuberculosis 
treatment, and ideally on a regular basis 
thereafter. ■
Acknowledgements
The TANDEM partners and collabo-
rators include: H Dockrell, J Cliff, C 
Eckold, D Moore, U Griffiths and Y 
Laurence from London School of Hy-
giene & Tropical Medicine, London, 
England; R Aarnouste, M Netea; R van 
Crevel, C Ruesen and E Lachmandas 
from Radboud University Medical 
Center, Nijmegen, Netherlands; S 
Kaufmann, M Beigier and R Golinski 
from Max Planck Institute for Infection 
Biology, Berlin Germany; S Joosten, T 
Ottenhoff, F Vrieling and M Haks from 
LUMC, Leiden, Netherlands; G Walzl, 
K Ronacher, S Malherbe, L Kleynhans, 
B Smith, K Stanley, G van der Spuy, A 
Loxton, N Chegou, M Bosman, L Thiart, 
C Wagman, H Tshivhula, M Selamolela, 
N Prins, W du Plessis, I van Rensburg 
and L du Toit from Stellenboch Uni-
versity, Cape Town, South Africa; J 
Fig. 2. Diagnostic accuracy of diabetes mellitus markers in patients with newly 
diagnosed tuberculosis recruited to the Concurrent Tuberculosis and Diabetes 
Mellitus study, by country, 2014–2016
Diagnostic test Area under ROC 
curve (95% CI)
Indonesia (649 patients)
2-steps RPG/POC HbA1c ≥ 6.5%
Point-of-care HbA1c ≥ 6.5% 0.98 (0.96–1.00)
Full TANDEM score ≥ 12.4 0.97 (0.94–1.00)
Random plasma glucose ≥ 11.1  mmol/L 0.95 (0.91–0.99)
Peru (562 patients)
2-step RPG/POC HbA1c ≥  6.5%
Point-of-care HbA1c ≥  6.5% 0.93 (0.89–0.98)
Full TANDEM score ≥ 12.4 0.95 (0.90–0.99)
Random plasma glucose  ≥ 11.1  mmol/L 0.86 (0.75–0.97)
Romania (469 patients)
2-step RPG/POC HbA1c ≥ 6.5%
Point-of-care HbA1c  ≥ 6.5% 0.69 (0.56–0.82)
Full TANDEM score ≥ 12.4 0.69 (0.58–0.79)
Random plasma glucose ≥ 11.1  mmol/L 0.49 (0.35–0.64)
South Africa (259 patients)
2-step RPG/POC HbA1c ≥ 6.5%
Point-of-care HbA1c ≥ 6.5% 0.72 (0.59–0.84)
Full TANDEM score ≥ 12.4 0.74 (0.61–0.87)
Random plasma glucose ≥ 11.1  mmol/L 0.60 (0.45–0.76)
Overall (1939 patients)
2-step RPG/POC HbA1c ≥ 6.5%
Point-of-care HbA1c ≥ 6.5% 0.81 (0.75–0.86)
Full TANDEM score ≥ 12.4 0.85 (0.81–0.90)
Random plasma glucose ≥ 11.1  mmol/L 0.75 (0.70–0.80)
Overall, conservative 
definition of diabetes mellitus
2-step RPG/POC HbA1c ≥ 6.5%
Point-of-care HbA1c ≥ 6.5% 0.93 (0.87–0.99)
Full TANDEM score  ≥ 12.4 0.95 (0.90–1.00)
Random plasma glucose ≥ 11.1  mmol/L 0.90 (0.83–0.97)
Sensitivity Specificity
%(95% CI)
0 10 20 30 40 50 60 70 80 90 100
CI: confidence interval; HbA1C: glycated haemoglobin; ROC: receiver operating characteristic curve; RPG/
POC; random plasma glucose point-of-care HbA1c test; TANDEM: Concurrent Tuberculosis and Diabetes 
Mellitus study.
Notes: In the two-step combination test, point-of-care HbA1c was included only if random plasma 
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and random plasma glucose. The standard definition of diabetes mellitus was laboratory-measured 
HbA1c ≥ 6.5%; conservative definition was HbA1c ≥ 7.0%.
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方法 在这项多中心、前瞻性的研究中，自 2014 年 1 月







随机血糖为临界值 ≥ 6.1 mmol/L 时，进行糖化血红
蛋白 (HbA1c) 床旁检测。
结果 新诊断结核病患者中，糖尿病的整体患病率
为 283/2185（13.0 ％ ；95 ％ 置 信 区 间，CI ：11.6–
14.4）。最准确的诊断指标是糖化血红蛋白 (HbA1c) 床




0.85 ；95％ 置信区间，CI ：0.81-0.90）。不同地点的指
标之间存在显著的异质性，但两步组合检测法在秘鲁
和印度尼西亚表现良好。







Précision des méthodes de dépistage du diabète utilisées pour les personnes atteintes de tuberculose en Afrique du Sud, en 
Indonésie, au Pérou et en Roumanie
Objectif Évaluer la performance des outils de diagnostic du diabète 
sucré, et notamment les méthodes de laboratoire et les cotes de risque 
clinique, chez les patients souffrant d'une tuberculose pulmonaire 
récemment diagnostiquée dans quatre pays à revenu intermédiaire.
Méthodes Dans le cadre d'une étude multicentrique et prospective, 
nous avons recruté 2185 patients atteints de tuberculose pulmonaire 
dans différents endroits en Afrique du Sud, en Indonésie, au Pérou et 
en Roumanie entre janvier 2014 et septembre 2016. En utilisant comme 
référence l'hémoglobine glyquée (HbA1c) mesurée en laboratoire, nous 
avons évalué la précision diagnostique de la glycémie aléatoire, de 
l'HbA1c sur le lieu d'intervention, de la glycémie à jeun, de la bandelette 
urinaire, des cotes de risque déjà publiées et récemment obtenues 
pour le diabète sucré et des mesures anthropométriques. Nous avons 
également analysé des combinaisons de tests, et notamment un test 
en deux étapes qui utilise l'HbA1c sur le lieu d'intervention lorsque la 
glycémie aléatoire initiale est ≥ 6,1 mmol/L.
Résultats La prévalence brute générale du diabète sucré chez les 
patients souffrant d'une tuberculose récemment diagnostiquée était 
de 283/2185 (13,0%; intervalle de confiance, IC, à 95%: 11,6–14,4). Le 
marqueur fournissant la meilleure précision diagnostique était l'HbA1c 
sur le lieu d'intervention (aire sous la courbe ROC: 0,81; IC à 95%: 
0,75–0,86). La meilleure précision diagnostique générale a été obtenue 
à l'aide d'une cote de risque calculée au moyen de l'âge, de l'HbA1c sur 
le lieu d'intervention et de la glycémie aléatoire (aire sous la courbe ROC: 
صخلم
اينامور ،ايقيرفأ بونج ،ويرب ،ايسينودنإ ،لسلاب ينباصلما صاخشلأا عم ةمدختسلما يركسلا ضرم صحف قرط ةقد
 كلذ في ماب  ،يركسلا  ضرم صيخشت تاودأ  ءادأ  مييقت  ضرغلا
 نيذلا  ضىرلما  ىدل  ،ةيريسرلا  رطاخلما  تاجردو ةيبرتخلما  قرطلا
 نادلب  ةعبرأ  نم  يوئرلا  لسلاب  ًاثيدح  مهتباصإ  صيخشت  مت
.لخدلا ةطسوتم
 2185 ـب ةناعتسلااب انمق ،زكارلما ةددعتم ةيقابتسا ةسارد في ةقيرطلا
 بونجو ويربو ايسينودنإ في عقاوم نم يوئرلا لسلا ضرمب اًضيرم
 لوليأ/برمتبس  لىإ  2014  نياث  نوناك/رياني  نم  اينامورو  ايقيرفإ
 برتخلما في تيلايزوكيلغلا ينبولغوميلها سايق قيرط نعو .2016
 لك صيخشت ةقد ىدم سايقب انمق ،سياسأ رايعمك (HbA1c)
 نكامأ  في  HbA1c  رابتخاو  ،يئاوشعلا  امزلابلا  زوكولج  نم
 تاجردو  ،لوبلا  سايقمو  ،مايصلا  ءانثأ  مدلا  زوكولجو  ،ةياعرلا
 تاسايقلاو  ،يركسلا  ءاد  نم  اثيدح  ةطبنتسلماو  ةروشنلما  رطاخلما
 ماب ،تارابتخلاا نم تاعوممج ليلحتب اضيأ انمق .ةيترموبورثنلأا
 نكامأ في HbA1c رابتخا مادختساب ينتوطخ نم رابتخا كلذ في
 وأ نم بركأ يئاوشعلا امزلابلا زوكولج ىوتسم ناك امدنع ةياعرلا
.ترل /لوميلم 6.1 يواسي
 نيذلا ضىرلما ينب يركسلا ضرلم ليكلا راشتنلاا لدعم ناك جئاتنلا
 ؛13.0%)  2185/283  وه لسلاب اًثيدح مهتباصإ صيخشت مت
 ةملاعلا  تناك.(14.4  لىإ  11.6  :ةقث  لصاف  ،95%  ةقث  لصافب
 ةياعرلا نكامأ في HbA1c رابتخا يه ةيصيخشت ةقد لضفأ تاذ
 لصافب ؛0.81 :ِلبقتسملل ليغشتلا ةيصاخ ىنحنم تتح ةحاسلما)
 مادختساب ةقتشلما رطلخا ةجرد تناك .(0.86 لىإ 0.75 :95% ةقث
 امزلابلا  زوكولجو  ،ةياعرلا  نكامأ  في  HbA1c  رابتخاو  ،رمعلا
 :ىنحنلما تتح ةحاسلما) ةماع ةيصيخشت ةقد لضفأ يه ،يئاوشعلا
 مدع  كانه  تناك  .(0.90  لىإ  0.81  :95%  ةقث  لصافب  ؛0.85
 نوكلما رابتخلاا نأ لاإ ،تاملاعلا لكل عقاولما ينب حضاو سناتج
.ويربو ايسينودنإ في اًديج ًءادأ مدق ينتوطخ نم
 رابتخا هيليو ،يئاوشعلا امزلابلا زوكولج رابتخلا نكمي جاتنتسلاا
 في  ةقدب  يركسلا  ضرم  صيخشت  ،ةياعرلا  نكامأ  في  HbA1c
 في  ديدش  عافترا  نم  نوناعي  نيذلا  كئلوأ  ةصاخو  ،لسلا  ضىرم
 في ةفلكت رثكلأا HbA1c رابتخا لىإ ةجالحا ليلقت عم ،مدلا ركس
 تانايب  عم  ءاوس ،ةديفم  رطلخا  تاجرد نوكت  دق  .ةياعرلا  نكامأ
 .ةحصلا نم ققحتلا بلطتت اهنكلو ،انهودب وأ ةيويح ةيئايميك
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0,85; IC à 95%: 0,81–0,90). Une forte hétérogénéité entre les différents 
endroits a été constatée pour tous les marqueurs, mais le test en deux 
étapes a donné de bons résultats en Indonésie et au Pérou.
Conclusion L'utilisation de la glycémie aléatoire suivie de l'HbA1c sur 
le lieu d'intervention permet de diagnostiquer avec précision le diabète 
chez les patients atteints de tuberculose, en particulier lorsqu'ils souffrent 
d'une importante hyperglycémie, tout en diminuant le besoin de tests 
HbA1c sur le lieu d'intervention, plus coûteux. Les cotes de risque 
associées ou non à des données biochimiques peuvent être utiles, mais 
doivent être validées. 
Резюме
Точность методов исследования, направленного на выявление сахарного диабета у пациентов с 
туберкулезом, проживающих в Индонезии, Перу, Румынии и Южной Африке
Цель Оценить эффективность инструментов диагностики 
сахарного диабета (включая лабораторные методы и показатели 
клинического риска) у пациентов с недавно диагностированным 
туберкулезом легких из четырех стран со средним уровнем 
доходов.
Методы С января 2014 года по сентябрь 2016 года авторы 
провели многоцентровое проспективное исследование, в 
котором приняли участие 2185 пациентов с туберкулезом легких, 
проживающих в Индонезии, Перу, Румынии и Южной Африке. 
Используя измеренный в лаборатории гликозилированный 
гемоглобин (HbA1c) в качестве общепринятого стандарта, авторы 
измерили диагностическую точность выборочного определения 
уровня глюкозы в плазме; уровня HbA1c, определяемого в месте 
предоставления медицинской помощи; уровня глюкозы в крови 
натощак и определения сахара в моче с помощью индикаторной 
полоски с учетом опубликованных и недавно полученных оценок 
риска заболевания сахарным диабетом и антропометрических 
измерений. Мы также проанализировали комбинации тестов, 
в том числе двухэтапный тест с использованием HbA1c, 
измеренного в месте предоставления медицинской помощи, при 
начальном случайном уровне глюкозы в плазме ≥ 6,1 ммоль/л.
Результаты Общая распространенность сахарного диабета 
среди пациентов с недавно выявленным туберкулезом составила 
283 случая на 2185 человек (13,0%, 95%-й доверительный 
интервал, ДИ: 11,6–14,4). Маркер с наибольшей диагностической 
точностью — HbA1c, измеренный в месте предоставления 
медицинской помощи (область под кривой ROC: 0,81; 95%-й 
ДИ: 0,75–0,86). Оценка риска в зависимости от возраста, HbA1c, 
измеренного в месте предоставления медицинской помощи, и 
выборочного определения глюкозы в плазме имела наилучшую 
общую диагностическую точность (область под кривой: 0,85; 95%-
й ДИ: 0,81–0,90). В различных местах наблюдалась существенная 
гетерогенность всех маркеров, при этом двухступенчатый 
комбинированный тест дал хорошие показатели для Индонезии 
и Перу.
Вывод Выборочно определяемый уровень глюкозы в плазме с 
последующим тестированием HbA1c в месте предоставления 
медицинской помощи может точно диагностировать диабет 
у пациентов с туберкулезом, особенно у пациентов с 
существенной гипергликемией, уменьшая необходимость в более 
дорогостоящем тестировании HbA1c в месте предоставления 
медицинской помощи. Оценки риска по данным биохимического 
анализа крови или без них могут быть полезными, но нуждаются 
в проверке.
Resumen
Precisión de los métodos de diagnóstico de diabetes utilizados en personas con tuberculosis en Indonesia, Perú, Rumanía y 
Sudáfrica
Objetivo Evaluar el rendimiento de las herramientas de diagnóstico para 
la diabetes mellitus, incluidos los métodos de laboratorio y los índices 
de riesgo clínico, en pacientes recién diagnosticados con tuberculosis 
pulmonar de cuatro países de ingresos medios.
Métodos En un estudio prospectivo multicéntrico, se seleccionaron 
2185 pacientes con tuberculosis pulmonar de algunas regiones de 
Indonesia, Perú, Rumanía y Sudáfrica entre enero de 2014 y septiembre 
de 2016. Usando hemoglobina glicosilada medida en laboratorio 
(HbA1c) como el patrón de excelencia, se midió la precisión diagnóstica 
de glucosa plasmática al azar, estando HbA1c en el punto de atención, 
glucemia en sangre en ayunas, tira reactiva de orina, índices de riesgo de 
diabetes mellitus publicados recientemente y medidas antropométricas. 
También se analizaron combinaciones de pruebas, incluida una prueba 
de dos pasos con HbA1c en el punto de atención cuando la glucosa 
plasmática aleatoria inicial fue ≥ 6,1mmol/L.
Resultados La prevalencia general cruda de diabetes mellitus entre 
los pacientes con tuberculosis recién diagnosticados fue de 283/2185 
(13,0 %, intervalo de confianza del 95 %, IC: 11,6–14,4). El marcador con 
la mejor precisión diagnóstica fue la HbA1c en el punto de atención 
(área bajo la curva característica operativa del receptor: 0,81; IC del 
95 %: 0,75–0,86). Un índice de riesgo derivado de la edad, la HbA1c 
en el punto de atención y la glucosa plasmática al azar obtuvieron la 
mejor precisión diagnóstica general (área bajo la curva: 0,85; IC del 95 %: 
0,81–0,90). Hubo una heterogeneidad sustancial entre las regiones para 
todos los marcadores, pero la prueba combinada de dos pasos funcionó 
de manera correcta en Indonesia y Perú.
Conclusión La glucosa plasmática al azar seguida de la prueba de 
HbA1c en el punto de atención puede diagnosticar con precisión la 
diabetes en pacientes con tuberculosis, particularmente en aquellos con 
hiperglucemia sustancial, mientras se reduce la necesidad de pruebas 
más costosas de HbA1c en el punto de atención. Los índices de riesgo 
con o sin datos bioquímicos pueden ser útiles, pero requieren validación.
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